Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Parathyroid hormone - Takeda

Drug Profile

Parathyroid hormone - Takeda

Alternative Names: 423562; ALX 111; Natpar; Natpara; NPSP-795; NPSP558; Parathyroid hormone (1-84) - Takeda; PREOS; Preotact; PTH (1-84); PTH 1-84; Recombinant human parathyroid hormone-1-84; rhPTH (1-84); rhPTH-1-84; SB-423562; SHP-635; SHP634

Latest Information Update: 15 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NPS Pharmaceuticals
  • Developer National Institutes of Health (USA); NPS Pharmaceuticals; Shire; Takeda; Takeda Pharmaceuticals International GmbH
  • Class Calcium regulators; Osteoporosis therapies; Peptide hormones; Recombinant proteins
  • Mechanism of Action Calcium-sensing receptor antagonists; Osteogenesis stimulants; Parathyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoparathyroidism
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypoparathyroidism; Postmenopausal osteoporosis
  • Phase II Hypocalcaemia
  • Discontinued Osteoporosis

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 28 Dec 2018 No recent reports of development identified for phase-I development in Hypoparathyroidism(In adolescents) in United Kingdom (SC, Injection)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top